bioRxiv Science⌕ Search

Biology subjects

Doshi, S.

Publications and source records attributed to Doshi, S..

2 recordsLinked to original sources

An optogenetics-compatible red fluorescent calcium indicator with negligible blue light photoactivation

Red genetically encoded calcium indicators (GECIs) are important tools for live cell and in vivo imaging. However, their application in optogenetic experiments has been limited by their complex photophysics, which can yield blue-light-induced artifacts. These photophysical drawbacks arise from the fluorescent protein (FP) used to construct the GECI. To address these limitations, we engineered novel red GECIs based on photostable red FPs, including mScarlet variants. After testing multiple design topologies and screening for calcium responses, we identified a lead variant, named ScaRCaMP-1.0. ScaRCaMP-1.0 exhibits moderate Ca2+ responses ({Delta}F/F0 = -13%) relative to other red GECIs, a tradeoff that appears to have enabled remarkable blue-light photostability at power densities exceeding 200 mW/mm2. We validated the performance of ScaRCaMP-1.0 in an optogenetic regime, and in vivo via fiber photometry. Finally, guided by structural predictions, we investigated the mechanism underlying ScaRCaMP responses. A pair of lysine residues on the surface of the FP appear to be important for controlling Ca2+ responses, and mutation of one residue (K132Y) notably increased the response size ({Delta}F/F0 = -22%) without compromising blue-light photostability. We call the improved variant ScaRCaMP-2.0. Taken together, these results establish ScaRCaMP as an optogenetics-compatible red GECI and demonstrate the potential of mScarlet-based fluorophores as a basis for generating photostable red biosensors.

neuroscience↗

The kidney protects against sepsis by enhancing the systemic release of Uromodulin to stimulate macrophage function

Sepsis is a significant cause of mortality in hospitalized patients. Concomitant development of acute kidney injury (AKI) increases sepsis mortality through unclear mechanisms. While electrolyte disturbances and toxic metabolite buildup during AKI could be important, it is possible that the kidney produces a protective molecule lost during sepsis with AKI. We previously demonstrated that systemic Tamm-Horsfall Protein (THP, uromodulin), a kidney-derived protein with immunomodulatory properties, falls in AKI. Using a mouse sepsis model without severe kidney injury, we show that the kidney increases circulating THP by enhancing basolateral release of THP from medullary thick ascending limb cells. In sepsis patients, changes in circulating THP are positively associated with critical illness. THP is also found de novo in injured lungs. Genetic ablation of THP in mice leads to increased mortality and bacterial burden during sepsis. Consistent with the increased bacterial burden, the presence of THP in vitro and in vivo leads macrophages and monocytes to upregulate a transcriptional program promoting cell migration, phagocytosis and chemotaxis and treatment of macrophages with purified THP increases phagocytosis. Rescue of septic THP-/- mice with exogenous systemic THP improves survival. Together, these findings suggest that through releasing THP, the kidney modulates the immune response in sepsis by enhancing mononuclear phagocyte function and systemic THP has therapeutic potential in sepsis. Significance StatementSepsis is a significant contributor to kidney injury as well as morbidity and mortality worldwide. Specific therapies to improve outcomes in sepsis with kidney injury have largely been limited to symptom management and infectious agent control, in part because it is unclear how kidney injury increases sepsis mortality. This paper describes the identification of Tamm-Horsfall protein, previously known to protect in ischemic models of AKI, as protective in preclinical models of sepsis. It demonstrates how the loss of THP leads to decreased mononuclear phagocyte function and diversity, increased pathogen burden and decreased survival. THP also increases in sepsis without severe kidney injury and concentrates in injured organs. Further study of THP in sepsis could lead to novel sepsis therapeutics.

immunology↗